A phase 2 study found baseline OCT features, such as greater outer retinal volume or thickness, in patients with non-exudative age-related macular degeneration may affect visual gains when treated with risuteganib.
“It was a dramatic difference looking at the eyes who got risuteganib who did respond vs. those who didn’t respond in terms of these outer retinal parameters,” Justis P. Ehlers, MD, said in discussion of the study at the virtual American Society of Retina Specialists meeting.
Ehlers and colleagues conducted the double-masked, placebo-controlled clinical study and
Uncategorized